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Humanity owes a great debt to quinine. Cinchona
alkaloids have been used to treat malaria for hundreds of
years after the arrival of cinchona bark in Europe in the
17th century, where it was mixed with rose leaves, lemon
juice and wine to treat the malarious patients of Essex
(Butler et al. 2010). While quinine has been largely
replaced by more effective and better-tolerated drugs in
the treatment of uncomplicated malaria, it remains the
standard treatment for severe malaria in many countries.
In Africa, where over 90% of the estimated 781 000
malaria-related deaths in 2009 occurred, quinine is ﬁrst-
line therapy for severe malaria in almost all countries
(WHO 2010).
Recent evidence shows that it is time to replace
quinine for severe malaria as well. A large randomized
trial conducted in Asia in 2005 found that parenteral
artesunate reduced overall mortality by 39% compared
with quinine (Dondorp et al. 2005). As a result, in 2006
WHO recommended artesunate as the treatment of
choice for adults, but considered there was insufﬁcient
evidence to extend this recommendation to children in
Africa. That evidence came in late 2010, from the largest
ever study of severe malaria (5425 children across
Africa), which found that artesunate reduced mortality
by 22.5% compared with quinine (Dondorp et al. 2010).
Importantly, there was no evidence in this or previous
studies of an increase in neurological sequelae in survi-
vors. These results were conﬁrmed by a recent Cochrane
meta-analysis that found an overall mortality reduction
of 39% among adults and 24% among children com-
pared to quinine (Sinclair et al. 2011), an identical
ﬁnding to the meta-analysis accompanying the African
trial (Dondorp et al. 2010).
So what now? WHO has just changed its guidelines to
put artesunate as the treatment of choice for severe
malaria everywhere (WHO 2011), and these recommen-
dations need to be disseminated to all relevant malaria
actors to support national guideline change where
needed. To date, only one African country (Nigeria) has
revised its guidelines to include artesunate for severe
malaria, and only as an alternative treatment (WHO
2010). Given the long history of quinine use, the
dissemination of national guidelines will need to be
accompanied by training to help shift health provider
habits and personal convictions. All this needs to be
properly supported, both by international donors and
through technical advice from WHO’s regional ofﬁces.
The challenge in translating evidence into practice
should never be underestimated, particularly when it
comes to malaria treatment, as recent history shows. In
2000, WHO recommended a policy shift in the manage-
ment of uncomplicated malaria from chloroquine to
artemisinin-based combination therapies (ACTs) because
of high levels of chloroquine resistance. Yet, despite
substantial evidence supporting the superior efﬁcacy of
ACTs, international donors and ministries of health in
malaria-endemic countries continued to support chloro-
quine use for several years, mainly because chloroquine
was a much cheaper drug (Attaran et al. 2004).
Similarly, the higher unit price of artesunate is likely to
be a barrier. Cost effectiveness studies, however, show that
when mortality and associated costs such as reduced side-
effect management and hospitalization are considered,
artesunate is cost effective (Lubell et al. 2009, 2011).
Furthermore, the cost of artesunate may fall as demand
increases. Nevertheless, for policy and practice to change in
the short-term, additional international funding support is
needed.
Another important potential concern is the limited
availability of quality-assured sources of artesunate.
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been pre-qualiﬁed by WHO, and malaria control pro-
grammes may be reluctant to make the switch as long as
consistency in supply is uncertain. In addition, quinine
production represents an important economic activity in a
number of malaria-endemic countries; in Burundi, for
example, quinine is one of the few drugs manufactured
in-country, making it more popular and more easily
accessible than imported antimalarial drugs (Amuasi et al.
2011). However, artemisinin, the raw material for
artesunate, is increasingly being produced in Africa,
including in Kenya, Tanzania and Uganda (http://
www.artepal.org), and as demand grows, supply should
logically follow.
Finally, it can be anticipated that calls for local evidence
may be made by national governments out of concern that
studies performed in other contexts may not apply to their
setting. MSF faced similar challenges when trying to move
from chloroquine to ACT (Guthmann et al. 2008). While
this may initially appear reasonable, the evidence to date
is broadly generalizable and the latest Cochrane review
concludes that further research to assess the efﬁcacy of
artesunate versus quinine is unnecessary (Sinclair et al.
2011). Patients should only be subjected to experimental
trials if there is real uncertainty about which drug is better
(CIOMS 2002), and while operational research may help
guide implementation, it would clearly be unethical to
delay implementation and subject patients to further drug
effectiveness studies.
Global funding for malaria control is already insufﬁ-
cient (Snow et al. 2010), and in the current economic
climate, donors may be reluctant to support a switch to
a more expensive treatment. However, replacing quinine
with artesunate is a clear cut intervention that has the
potential to save nearly 200 000 lives each year and the
total annual cost of providing artesunate for treating all
cases of severe malaria worldwide would likely be less
than $US 50 million (MSF 2011). For African countries
to make the switch, strong international support will be
required to provide additional funds to support drug
procurement and training costs and send a clear message
to manufacturers that quality sources of artesunate are
needed.
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